Brief: Spectral Medical Provides Update On Tigris Clinical Trial And Other Business Developments
12/01/2023 12:37
Spectral Medical Inc EDT.TO :
* SPECTRAL MEDICAL PROVIDES UPDATE ON TIGRIS CLINICAL TRIAL
AND
OTHER BUSINESS DEVELOPMENTS
* SPECTRAL MEDICAL INC - 50 PATIENTS RANDOMIZED TO DATE OUT
OF 150
TOTAL TARGET TO BE ENROLLED
* SPECTRAL MEDICAL INC - INCREASING OUR TRIAL SITES FOR 2023
* SPECTRAL MEDICAL INC - ANTICIPATE PUBLICATION OF RESEARCH
STUDY
RESULTS IN EARLY 2023
* SPECTRAL MEDICAL - TIGRIS TRIAL END POINT IS REDUCTION IN
28-DAY
MORTALITY IN SUBJECTS WITH SEPTIC SHOCK USING PMX HEMOPERFUSION
CARTRIDGE
* SPECTRAL MEDICAL INC - REMAIN HIGHLY OPTIMISTIC ABOUT
OUTLOOK
FOR TIGRIS TRIAL, WHICH WE EXPECT TO COMPLETE IN 2023
Source text for Eikon: ID:nGNX7zg4Md
Further company coverage: EDT.TO
Recent news on Spectral Medical
See all newsBrief: Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA
Canada's Spectral Medical Q2 revenue falls on lower reagent sales
Brief: Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial
Canada's Spectral Medical Q1 revenue rises 56%, net loss narrows
Spectral Medical Q3 revenue up 34%